Citius Pharmaceuticals, Inc. · NASDAQ:CTXR

Citius Pharmaceuticals — Investor Presentation (April 2022)

29 slides from Citius Pharmaceuticals's investor presentation, April 2022

  1. Slide 1: Citius Pharmaceuticals Corporate Overview April 2022

    CLICK TO EDIT MASTER TITLE STYLE Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) Corporate Overview APRIL 2022 NASDAQ: CTXR

  2. Slide 2: Forward-Looking Statements

    CLICK TO EDIT MASTER STATEMENTS FORWARD-LOOKING TITLE STYLE This presentation has been prepared by Citius Pharmaceuticals, Inc. (the “Company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promi

  3. Slide 3: Citius: Building a Biotech Platform

    CLICK CITIUS:TO EDIT MASTER BUILDING TITLEPLATFORM A BIOTECH STYLE Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products LMB merges with Citius CTXR raises Multiple catalysts Pharmaceuticals, Inc. (CTXR); $127.6M

  4. Slide 4: Investment Highlights

    CLICK TO EDITHIGHLIGHTS INVESTMENT MASTER TITLE STYLE • Five Active Programs • I/ONTAK: purified reformulation of IL-2 diphtheria toxin fusion protein for CTCL DIVERSIFIED PHASE 3 • Mino-Lok® : potential to be first and only FDA-approved product to salvage infected PIPELINE WITH CVCs causing CRBSI/C

  5. Slide 5: Diversified Pipeline with Five Active Programs

    CLICK TO EDIT DIVERSIFIED MASTERWITH PIPELINE TITLEFIVE STYLE ACTIVE PROGRAMS ESTIMATED INVESTIGATIONAL ANTICIPATED PROGRAM MARKET PRECLINICAL PHASE I PHASE II PHASE III INDICATION MILESTONES (WW) I/ONTAK IL-2R CANCER >$300M BLA 2022 (E7777) IMMUNOTHERAPY* MINO-LOK® TREAT CVC > $1.8B Complete (CITI-

  6. Slide 6: Management Team with Proven Track Record

    CLICK TO EDIT MASTER MANAGEMENT TITLE TEAM WITH STYLETRACK RECORD PROVEN LEONARD MAZUR MYRON HOLUBIAK JAIME BARTUSHAK DR. MYRON CZUCZMAN GARY TALARICO CHAIRMAN & CEO* VICE CHAIRMAN & CO-FOUNDER* EVP, CFO & CBO* EVP, CHIEF MEDICAL OFFICER EVP, OPERATIONS KELLY CREIGHTON CATHERINE KESSLER JAY WADEKAR

  7. Slide 7: Scientific Advisory Board of Leading KOLs

    CLICK TO EDIT SCIENTIFIC MASTERBOARD ADVISORY TITLE STYLE OF LEADING KOLS INFECTIOUS DISEASE / CANCER ADVISORS CELL THERAPY ADVISORS Isaam Raad, MD Michael A. Matthay, MD University of Texas MD Anderson Cancer Center University of California at San Francisco (UCSF) Mark Rupp, MD Lorraine B. Ware, MD

  8. Slide 8: I/ONTAK (E7777)

    CLICK TO EDIT MASTER TITLE STYLE I/ONTAK (E7777) PHASE 3 NASDAQ: CTXR 8

  9. Slide 9: A Novel Immunotherapy with a Dual MOA

    CLICK TOIMMUNOTHERAPY A NOVEL EDIT MASTER TITLE STYLE WITH A DUAL MOA I/ONTAK is an engineered IL-2-diphtheria toxin fusion protein with a unique dual mechanism of action • purified and more bioactive formulation of previously marketed ONTAK® • targets both malignant T-cells and immunosuppressive Tr

  10. Slide 10: I/ONTAK: Cancer Agent Nearing FDA Submission

    CLICK TOPHASE I/ONTAK: EDIT MASTER TITLE 3 CANCER STYLE AGENT NEARING FDA SUBMISSION Reformulated oncology asset with an attractive near-term revenue opportunity Enrollment in BLA • Improved formulation of previously- Phase 3 trial submission approved drug (ONTAK) for treatment completed (LPO) antic

  11. Slide 11: What is Cutaneous T-Cell Lymphoma (CTCL)?

    CLICK TOCUTANEOUS WHAT IS EDIT MASTER TITLELYMPHOMA T-CELL STYLE (CTCL)? Considered to be incurable, CTCL is a CTCL accounts for general term for T-cell lymphoma that approximately 4% of all non- involve the skin, but may also involve the Hodgkin lymphoma (NHL) blood, lymph nodes, and internal organ

  12. Slide 12: I/ONTAK Pivotal Phase 3 Trial: Completed

    CLICK TOPIVOTAL I/ONTAK EDIT MASTER PHASETITLE STYLE 3 TRIAL: COMPLETED Single Arm trial completed December 2021 21 days DAY 1 DAY 2 DAY 3 DAY 4 DAY 5 n=711 CYCLE DOSING: 9mcg/kg/day IV CYCLE • The FDA provided written comments in December 2021 indicating that their efficacy evaluation will be based

  13. Slide 13: Results: I/ONTAK Phase 3 Trial Topline

    CLICK TORESULTS: TOPLINE EDIT MASTER TITLE I/ONTAK STYLE3 TRIAL PHASE Topline results of I/ONTAK®: consistent with the prior formulation ORR1 ORR Independent (IRC) Investigator Stage Independent Primary Investigator Stage I-III I-III Efficacy Analysis Set2 Efficacy Analysis Set2 Primary Efficacy Eff

  14. Slide 14: Well-Positioned Among Existing Targeted Therapies

    CLICK TO EDIT MASTER WELL-POSITIONED TITLE AMONG STYLE TARGETED THERAPIES EXISTING With no single SOC, I/ONTAK expected to be an important option as the only IL-2R targeted therapy CD30 antigen directed1 I/ONTAK (E7777) CCR4 targeted2 (denileukin diftitox) targets IL-2 receptor expressed on malignan

  15. Slide 15: Multi-Layered Protection Through IP and Exclusivity

    CLICK TO EDIT MASTER MULTI-LAYERED TITLE STYLE PROTECTION THROUGH IP AND EXCLUSIVITY Proprietary Manufacturing Orphan Drug Designation Process granted for CTCL and PTCL trade secret (eligible for 7 years of marketing exclusivity) BLA Exclusivity Patents Pending eliminates biosimilar for I/O use as c

  16. Slide 16: Mino-Lok

    CLICK TO EDIT MASTER TITLE STYLE MINO-LOK® PHASE 3 NASDAQ: CTXR 16

  17. Slide 17: Late-Stage Candidate: Mino-Lok

    CLICK TOPRODUCT LATE-STAGE EDIT MASTER TITLE STYLE CANDIDATE: MINO-LOK ® First and Only antibiotic lock therapy under investigation to sterilize and salvage infected Central Venous Catheters (CVCs) 7 Million ~500,000 CRBSI/CLABSI infections Central Venus Catheters annually in the U.S.** (CVCs) used

  18. Slide 18: Current Standard of Care Is a Poor Option

    CLICK TO EDIT CURRENT MASTER STANDARD OFTITLE CARESTYLE IS A POOR OPTION Removing & replacing infected CVCs has multiple limitations • Limited availability of other vascular sites • Does not address need to maintain infusion therapy • Potential for complications: infectious, thrombotic and mechanica

  19. Slide 19: Potential Gold Standard in CLABSI Treatment

    CLICK TO EDIT POTENTIAL GOLDMASTER TITLE IN STANDARD STYLE CLABSI TREATMENT Mino-Lok® addresses the complications, discomfort and cost of CVC removal and replacement ✓ Limited duration IV therapy 5-7 DAYS ✓ Limits disruption of infusion therapy ✓ Ease of Administration • Locking a catheter is a well

  20. Slide 20: Mino-Lok Phase 2b Trial Results

    CLICK®TO MINO-LOK EDIT 2B PHASE MASTER TITLE STYLE Mino-Lok® demonstrated a strong safety and efficacy signal TRIAL RESULTS Mino-Lok Arm Control Arm Parameter N % N % Pat i ent s 30 100% 60 100% 100% Effective in salvaging CVCs in all Cancer Type patients treated with Mino-Lok® - Hemat ol ogi c 20 6

  21. Slide 21: Mino-Lok Phase 3 Pivotal Trial Underway

    CLICK TO EDIT MINO-LOK MASTER ® PHASE TITLE TRIAL 3 PIVOTAL STYLEUNDERWAY Multi-center, randomized, open label, blinded assessor, active control superiority study Active Arm Mino-Lok® Solution Anticipated median Patients with time of CRBSI R 21 days vs. 38 days (92 events) to achieve Control Arm sig

  22. Slide 22: IP & Regulatory Protections

    CLICK TO EDIT MASTER IP & REGULATORY TITLE STYLE PROTECTIONS Mino-Lok® is supported by a robust intellectual property portfolio with protection through 2036 Qualified Infectious Disease Product (US) • Priority Review reduces NDA review time from 12 to 6 months • Additional 5 years of market exclusiv

  23. Slide 23: Halo-Lido

    CLICK TO EDIT MASTER TITLE STYLE HALO-LIDO Halobetasol/Lidocaine Prescription Strength Topical for Symptomatic Hemorrhoid Treatment NASDAQ: CTXR 23

  24. Slide 24: Halo-Lido At-a-Glance

    CLICK TO EDIT HALO-LIDO MASTER TITLE STYLE AT-A-GLANCE Would be the first FDA-approved prescription product to treat hemorrhoids in the US • Based on the results of Phase 2 trial in 240 patients, CTXR elected to use super potent steroid Halobetasol propionate (HBP), maintained Lidocaine HCl (LH) and

  25. Slide 25: Summary

    CLICK TO EDIT MASTER TITLE STYLE SUMMARY NASDAQ: CTXR 25

  26. Slide 26: Financial Summary and Capitalization

    CLICK SUMMARY* FINANCIAL TO EDIT MASTER TITLE STYLE % OF FULLY CURRENT CAPITALIZATION SHARES Bandwidth to Execute DILUTED • $65.4M cash & equivalents as of 12/31/21 BASIC SHARES OUTSTANDING 146,029,630 74.8% • $5.5M R&D expense Q1 2022 WARRANTS 40,136,844 20.6% • Runway into 2023 OPTIONS 9,020,171 4

  27. Slide 27: Platform Poised for Growth in 2022

    CLICK TO PLATFORM BIOTECH EDIT MASTER TITLEFOR POISED STYLE GROWTH IN 2022 Multiple value-driving catalysts expected in 2022 Mino-Lok® Phase 3 trial completion I/ONTAK BLA anticipated 2022 submission anticipated 2H 2022 Halo-Lido Phase 2b trial expected to begin 1H 2022 I/ONTAK Pivotal Phase 3 trial

  28. Slide 28: Investment Highlights

    CLICK TO EDITHIGHLIGHTS INVESTMENT MASTER TITLE STYLE • Five Active Programs • I/ONTAK: purified reformulation of IL-2 diphtheria toxin fusion protein for CTCL DIVERSIFIED PHASE 3 • Mino-Lok® : potential to be first and only FDA-approved product to salvage infected PIPELINE WITH CVCs causing CRBSI/C

  29. Slide 29: Contact Information

    CLICK TO EDIT MASTER TITLE STYLE Citius Pharmaceuticals, Inc. 11 Commerce Drive First Floor Cranford, NJ 07016 www.citiuspharma.com Investor Relations Contact Ilanit Allen ir@citiuspharma.com NASDAQ: CTXR

Citius Pharmaceuticals — Investor Presentation (April 2022) on 6ix